Construction of an Infectious Full-Length cDNA Clone of the Porcine Enteric Calicivirus RNA Genome
Porcine enteric calicivirus (PEC) is a member of the genus Sapovirus in the family Caliciviridae. This virus causes diarrheal illness in pigs, and is presently the only enteric calicivirus that can be grown in cell culture. In addition to its relevance to veterinary medicine as a diarrheal agent in pigs, PEC serves as an important model for the study of enteric caliciviruses that cause diarrhea and that cannot be grown in cell culture (including the noroviruses represented by Norwalk virus).
Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics
Novel Kinase Inhibitory Aplithianines
Summary
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:
Reverse Thiazine Kinase Inhibitors
Summary
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:
Novel Kinase Inhibitory Thiazines
Summary
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:
Pyruvate Kinase M2 Activators for the Treatment of Cancer
T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy
Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation of CDKN2A is highly prevalent in melanoma, gastrointestinal and pancreatic cancers. Through germline mutations, CDKN2A is associated with predisposition for a variety of cancers, including melanoma and pancreatic cancers. Despite the high frequency of CDKN2A mutations in cancer, there have been no successful therapies targeting these mutations to date.
Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a hydrogel-based delivery system for the local administration of tofacitinib to improve transplant outcomes.
HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K
Summary:
The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target PIK3CA mutations to treat patients with tumors expressing these mutations in the context of HLA-DPA1*01:03:01, HLA-DPB1*04:01:01 or HLA-DRB1*04:01.
Description of Technology: